Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scan study aims to unlock mystery of auditory hallucinations

NCT ID NCT07003529

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study uses MRI scans to investigate whether a small brain area called the inferior colliculi plays a role in auditory hallucinations in people with schizophrenia. Researchers will compare brain activity in 40 participants—20 with hallucinations and 20 without—while they listen to sounds and at rest. The goal is to understand how these brain regions might fail to filter out internal signals, leading to hearing voices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help explain the brain mechanisms behind auditory hallucinations in schizophrenia, potentially guiding future treatments.
What could go wrong
This is a small, early-stage imaging study, not a treatment trial. It may not find clear differences, and any insights would need much more research to become useful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * DSM-5 diagnosis of schizophrenic disorder (based on clinical assessment and confirmed by the MINI 7.0 interview) * Patient with a schizophrenic disorder lasting ≤ 20 years * Patient treated in a psychiatric unit as an inpatient (in non-specialized care) or outpatient or under a mandatory ambulatory psychiatric care programme * Clinical condition compatible with imaging based on clinical judgment * Ability to understand, write, and read French Specific inclusion criteria for the group (SCZ+/HA+) • Patient with a PANSS score (question P3 regarding hallucinations) ≥ 4 (corresponds to PANSS (P3) 4, 5, 6, and 7 patients) AND having experienced hallucinations in the past 15 days. Specific inclusion criteria for the control group • Patient with a PANSS score (question P3 regarding hallucinations) = 1) AND having not experienced any hallucinations in the past 15 days. Exclusion Criteria: * The patient is under safeguard of justice or state guardianship * Contraindications to magnetic resonance imaging, including severe claustrophobia, based on clinical judgment. * Congenital or acquired deafness * Suicide risk, based on clinical judgment * Patient with moderate to severe intellectual disability, based on medical records * Patient with moderate to severe neurocognitive disorders, based on medical records * Patient receiving anticholinergic therapy (biperiden-Akineton, trihexyphenidyl-Artane, tropatepine-Lepticur) * Patient participating in an interventional study involving a drug or medical device, or a Category 1 RIPH within 3 months prior to inclusion * Person under judicial protection * Pregnant, parturient, or breastfeeding woman * Person unable to express consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hallucinations, auditory are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hallucinations schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hallucinations, auditory Schizophrenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nîmes, Hôpital Universitaire Carémeau

    RECRUITING

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.